# AMPECT (NCT02494570)

> A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02494570
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Aadi Bioscience, Inc.
- Conditions: Malignant PEComa
- Interventions: nab-Sirolimus
- Enrollment: 34
- Primary outcome: Objective Overall Response Rate (ORR)

## Commentary we found

- YouTube: 6
- Podcasts: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=ampect-nct02494570

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02494570", "email": "<work email>"}; the inbox owner confirms by the emailed link.